Anavex Life Sciences fires CEO Christopher Missling

9 articles · Updated · MarketWatch · May 6

The company said Wednesday that an independent special board committee also asked Missling to resign as a director, and named former clinical development executive Terrie Kellmeyer interim chief executive.
Anavex did not disclose the conduct behind the dismissal, saying only that it was inconsistent with company policy.
Missling had led the clinical-stage biopharmaceutical company since July 2013, making the abrupt leadership change a significant governance shift.

Is the sudden ouster of Anavex's CEO a sign of strong governance or a crisis that could derail its lead drug?

What 'inconsistent conduct' led to the CEO's firing just as Anavex's Alzheimer's drug shows promise?